Kura Hopes to Raise $100M in Public Offering on Heels of Clinical Data

Kura Oncology has announced plans for a $100 million underwritten public offering to fund the development of its three candidate drugs, invest pipeline research and development, and provide general working capital. The company has approximately $406 million in cash, cash equivalents and investments, which it expects will fund current operations until Q4 2025. However, Kura's pre-market share val..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms

Elevation Oncology Announces Pricing of $50 Million Public Offering

Elevation Oncology, a company focused on developing selective cancer therapies for solid tumors with significant unmet medical needs, has announced the pricing of an underwritten public offering of common stock and pre-funded warrants to purchase shares of common stock. The combined offering price is $2.2500 per share of common stock and accompanying warrant and $2.2499 per pre-funded warrant an..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms